Select Medical Holdings Corporation Announces Results For Its Second Quarter Ended June 30, 2020

Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced results for its second quarter ended June 30, 2020.

 

MECHANICSBURG, Pa., July 30, 2020 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its second quarter ended June 30, 2020.

For the second quarter ended June 30, 2020, net operating revenues were $1,232.7 million, compared to $1,361.4 million for the same quarter, prior year. Income from operations was $119.5 million for the second quarter ended June 30, 2020, compared to $124.9 million for the same quarter, prior year. For the second quarter ended June 30, 2020, income from operations included other operating income of $55.0 million related to the recognition of payments received under the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, for loss of revenue and health care related expenses attributable to the coronavirus disease 2019 ("COVID-19"). Net income increased 12.5% to $67.5 million for the second quarter ended June 30, 2020, compared to $60.0 million for the same quarter, prior year. Net income included a pre-tax gain on sale of businesses of $0.3 million for the second quarter ended June 30, 2020. Adjusted EBITDA was $178.8 million for the second quarter ended June 30, 2020, compared to $186.2 million for the same quarter, prior year. Earnings per common share was $0.39 on a fully diluted basis for the second quarter ended June 30, 2020, compared to $0.33 for the same quarter, prior year. Adjusted earnings per common share was $0.38 on a fully diluted basis for the second quarter ended June 30, 2020, compared to $0.33 for the same quarter, prior year. Adjusted earnings per common share excludes the gain on sale of businesses and its related tax effects for the second quarter ended June 30, 2020. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

For the six months ended June 30, 2020, net operating revenues were $2,647.4 million, compared to $2,686.0 million for the same period, prior year. Income from operations increased 4.9% to $248.2 million for the six months ended June 30, 2020, compared to $236.6 million for the same period, prior year. For the six months ended June 30, 2020, income from operations included other operating income of $55.0 million related to the recognition of payments received under the Provider Relief Fund for loss of revenue and health care related expenses attributable to COVID-19. Net income increased 21.7% to $137.9 million for the six months ended June 30, 2020, compared to $113.3 million for the same period, prior year. Net income included a pre-tax gain on sale of businesses of $7.5 million and $6.5 million for the six months ended June 30, 2020 and 2019, respectively. Adjusted EBITDA increased 2.7% to $366.1 million for the six months ended June 30, 2020, compared to $356.4 million for the same period, prior year. Earnings per common share was $0.78 on a fully diluted basis for the six months ended June 30, 2020, compared to $0.63 for the same period, prior year. Adjusted earnings per common share was $0.75 on a fully diluted basis for the six months ended June 30, 2020, compared to $0.60 for the same period, prior year. Adjusted earnings per common share excludes the gain on sale of businesses and related tax effects for both the six months ended June 30, 2020 and 2019. The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table IX of this release. A reconciliation of earnings per common share to adjusted earnings per common share is presented in table X of this release.

Please refer to "Effects of the COVID-19 Pandemic on Select Medical's Results of Operations" below for further discussion.

Company Overview

Select Medical is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States based on number of facilities.   Select Medical's reportable segments include the critical illness recovery hospital segment, the rehabilitation hospital segment, the outpatient rehabilitation segment, and the Concentra segment. As of June 30, 2020, Select Medical operated 101 critical illness recovery hospitals in 28 states, 29 rehabilitation hospitals in 12 states, and 1,757 outpatient rehabilitation clinics in 37 states and the District of Columbia. Select Medical's joint venture subsidiary Concentra operated 522 occupational health centers in 41 states. Concentra also provides contract services at employer worksites and Department of Veterans Affairs community-based outpatient clinics. At June 30, 2020, Select Medical had operations in 47 states and the District of Columbia. Information about Select Medical is available at www.selectmedical.com.

CARES Act Provider Relief Fund

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted. The CARES Act provided additional waivers, reimbursement, grants and other funds to assist health care providers during the coronavirus disease 2019 ("COVID-19") pandemic, including $100.0 billion in appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to the coronavirus, and for reimbursing eligible health care providers for lost revenues and health care related expenses that are attributable to COVID-19.

For the three and six months ended June 30, 2020, Select Medical recognized approximately $55.0 million of other operating income related to payments received under the Provider Relief Fund for loss of revenue and health care related expenses attributable to COVID-19. $54.2 million of other operating income is included within the operating results of Select Medical's other activities; $0.8 million of other operating income is included in the operating results of Select Medical's Concentra segment.

Critical Illness Recovery Hospital Segment

For the second quarter ended June 30, 2020, net operating revenues for the critical illness recovery hospital segment increased 12.7% to $519.6 million, compared to $461.1 million for the same quarter, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 39.9% to $89.7 million for the second quarter ended June 30, 2020, compared to $64.1 million for the same quarter, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 17.3% for the second quarter ended June 30, 2020, compared to 13.9% for the same quarter, prior year. Certain critical illness recovery hospital key statistics are presented in table VII of this release for both the second quarters ended June 30, 2020 and 2019.

For the six months ended June 30, 2020, net operating revenues for the critical illness recovery hospital segment increased 11.0% to $1,020.1 million, compared to $918.7 million for the same period, prior year. Adjusted EBITDA for the critical illness recovery hospital segment increased 30.0% to $178.3 million for the six months ended June 30, 2020, compared to $137.1 million for the same period, prior year. The Adjusted EBITDA margin for the critical illness recovery hospital segment was 17.5% for the six months ended June 30, 2020, compared to 14.9% for the same period, prior year. Certain critical illness recovery hospital key statistics are presented in table VIII of this release for both the six months ended June 30, 2020 and 2019.

Rehabilitation Hospital Segment

For the second quarter ended June 30, 2020, net operating revenues for the rehabilitation hospital segment increased 5.2% to $168.7 million, compared to $160.4 million for the same quarter, prior year. Adjusted EBITDA for the rehabilitation hospital segment was $27.6 million for the second quarter ended June 30, 2020, compared to $30.0 million for the same quarter, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 16.4% for the second quarter ended June 30, 2020, compared to 18.7% for the same quarter, prior year. For the second quarter ended June 30, 2019, the Adjusted EBITDA results for the rehabilitation hospital segment included start-up losses of approximately $6.0 million. Certain rehabilitation hospital key statistics are presented in table VII of this release for both the second quarters ended June 30, 2020 and 2019.

For the six months ended June 30, 2020, net operating revenues for the rehabilitation hospital segment increased 11.4% to $350.7 million, compared to $314.9 million for the same period, prior year. Adjusted EBITDA for the rehabilitation hospital segment increased 18.7% to $66.2 million for the six months ended June 30, 2020, compared to $55.8 million for the same period, prior year. The Adjusted EBITDA margin for the rehabilitation hospital segment was 18.9% for the six months ended June 30, 2020, compared to 17.7% for the same period, prior year. For the six months ended June 30, 2019, the Adjusted EBITDA results for the rehabilitation hospital segment included start-up losses of approximately $8.8 million. Certain rehabilitation hospital key statistics are presented in table VIII of this release for both the six months ended June 30, 2020 and 2019.

Outpatient Rehabilitation Segment

For the second quarter ended June 30, 2020, net operating revenues for the outpatient rehabilitation segment  were $167.1 million, compared to $261.9 million for the same quarter, prior year. The outpatient rehabilitation segment incurred Adjusted EBITDA losses of $6.3 million for the second quarter ended June 30, 2020, compared to Adjusted EBITDA of $42.6 million for the same quarter, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was (3.8)% for the second quarter ended June 30, 2020, compared to 16.3% for the same quarter, prior year. Certain outpatient rehabilitation key statistics are presented in table VII of this release for both the second quarters ended June 30, 2020 and 2019.

For the six months ended June 30, 2020, net operating revenues for the outpatient rehabilitation segment  were $422.4 million, compared to $508.8 million for the same period, prior year. Adjusted EBITDA for the outpatient rehabilitation segment was $20.8 million for the six months ended June 30, 2020, compared to $71.6 million for the same period, prior year. The Adjusted EBITDA margin for the outpatient rehabilitation segment was 4.9% for the six months ended June 30, 2020, compared to 14.1%  for the same period, prior year. Certain outpatient rehabilitation key statistics are presented in table VIII of this release for both the six months ended June 30, 2020 and 2019.

Concentra Segment

For the second quarter ended June 30, 2020, net operating revenues for the Concentra segment were $312.3 million, compared to $413.5 million for the same quarter, prior year. Adjusted EBITDA for the Concentra segment was $41.5 million for the second quarter ended June 30, 2020, compared to $76.1 million for the same quarter, prior year. The Adjusted EBITDA margin for the Concentra segment was 13.3% for the second quarter ended June 30, 2020, compared to 18.4% for the same quarter, prior year. Certain Concentra key statistics are presented in table VII of this release for both the second quarters ended June 30, 2020 and 2019.

For the six months ended June 30, 2020, net operating revenues for the Concentra segment were $710.9 million, compared to $809.8 million for the same period, prior year. Adjusted EBITDA for the Concentra segment was $103.0 million for the six months ended June 30, 2020, compared to $142.3 million for the same period, prior year. The Adjusted EBITDA margin for the Concentra segment was 14.5% for the six months ended June 30, 2020, compared to 17.6% for the same period, prior year. Certain Concentra key statistics are presented in table VIII of this release for both the six months ended June 30, 2020 and 2019.

Effects of the COVID-19 Pandemic on Select Medical's Results of Operations

The continuing implications of the COVID-19 pandemic on Select Medical's results of operations and overall financial performance remain uncertain. Select Medical has provided net operating revenues and certain operating statistics to assist readers in understanding how the COVID-19 pandemic impacted each of its segments during the three and six months ended June 30, 2020.

Critical Illness Recovery Hospital Segment.  Select Medical's critical illness recovery hospitals are a key component of the inpatient hospital continuum of care. Both the Centers for Medicare & Medicaid Services ("CMS") and Congress acted to temporarily suspend certain regulations concerning length of stay requirements, which apply to Select Medical's critical illness recovery hospitals, in order to facilitate the transfer of patients from general acute care hospitals. This was done in order to expand hospital bed capacity to care for COVID-19 patients. COVID-19 has become more prevalent in certain markets that Select Medical serves; as a result, Select Medical's critical illness recovery hospitals have admitted patients with COVID-19 and have faced the challenging task of treating those patients while also taking measures to protect their patients and staff members who do not have COVID-19. The pandemic has caused, and will continue to cause, disruptions in Select Medical's critical illness recovery hospitals, which include, in some cases, the addition or reduction of beds, the creation of isolated units and spaces, temporary increases or restrictions on admissions, the incurrence of additional costs, staff illnesses, and the increased use of contract clinical labor.

The following table shows the trend in net operating revenues and patient day volume for each of the periods presented, as well as the number of critical illness recovery hospitals Select Medical operated at the end of each period.

   

One Month Ended

 

Three Months Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

2020

                               

Critical illness recovery hospital

                               

Net operating revenues

 

$

163,238

   

$

165,375

   

$

171,908

   

$

171,445

   

$

178,223

   

$

169,958

   

$

519,626

   

$

1,020,147

 

Patient days

 

90,783

   

87,844

   

91,831

   

90,710

   

95,191

   

90,988

   

276,889

   

547,347

 

Occupancy rate

 

69

%

 

72

%

 

70

%

 

71

%

 

72

%

 

71

%

 

72

%

 

71

%

Number of hospitals owned

 

100

   

100

   

100

   

100

   

100

   

100

   

100

   

100

 

2019

                               

Critical illness recovery hospital

                               

Net operating revenues

 

$

149,799

   

$

145,586

   

$

162,149

   

$

156,231

   

$

156,422

   

$

148,490

   

$

461,143

   

$

918,677

 

Patient days

 

86,238

   

80,806

   

91,085

   

88,357

   

89,350

   

85,153

   

262,860

   

520,989

 

Occupancy rate

 

69

%

 

71

%

 

73

%

 

70

%

 

69

%

 

68

%

 

69

%

 

70

%

Number of hospitals owned

 

96

   

96

   

96

   

99

   

99

   

99

   

99

   

99

 

The following table summarizes the changes in net operating revenues and patient day volume for 2020, as compared to the same period in 2019, for each of the periods presented.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

Critical illness recovery hospital

                               

Net operating revenues

 

9.0

%

 

13.6

%

 

6.0

%

 

9.7

%

 

13.9

%

 

14.5

%

 

12.7

%

 

11.0

%

Patient days

 

5.3

%

 

8.7

%

 

0.8

%

 

2.7

%

 

6.5

%

 

6.9

%

 

5.3

%

 

5.1

%

Rehabilitation Hospital Segment.  Select Medical's rehabilitation hospitals receive most of their admissions from general acute care hospitals. Both CMS and Congress acted to temporarily suspend certain regulations that govern admissions into rehabilitation hospitals in order to facilitate the transfer of patients from general acute care hospitals and critical illness recovery hospitals. This was done in order to expand hospital bed capacity to care for COVID-19 patients. COVID-19 has become more prevalent in certain markets that Select Medical serves; as a result, Select Medical's rehabilitation hospitals have admitted patients with COVID-19 and have faced the challenging task of treating those patients while also taking measures to protect their patients and staff members who do not have COVID-19. The pandemic has caused, and will continue to cause, disruptions in Select Medical's rehabilitation hospitals, which include, in some cases, the addition or reduction of beds, the creation of isolated units and spaces, temporary restrictions on admissions, the incurrence of additional costs, staff illnesses, and the increased use of contract clinical labor. At the beginning of the pandemic, elective surgeries at hospitals and other facilities were suspended, which reduced the need for inpatient rehabilitation services. Beginning in May, state governors and health departments began to ease the restrictions imposed at the beginning of the pandemic and hospitals began to perform elective surgeries again, which has increased the need for the services provided by Select Medical's rehabilitation hospitals.

The following table shows the trend in net operating revenues and patient day volume for each of the periods presented, as well as the number of rehabilitation hospitals Select Medical operated at the end of each period.

   

One Month Ended

 

Three Months

Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

2020

                               

Rehabilitation hospital

                               

Net operating revenues

 

$

61,673

   

$

60,690

   

$

59,656

   

$

45,878

   

$

57,815

   

$

64,974

   

$

168,667

   

$

350,686

 

Patient days

 

32,111

   

31,813

   

30,644

   

23,553

   

29,787

   

30,741

   

84,081

   

178,649

 

Occupancy rate

 

79

%

 

84

%

 

76

%

 

61

%

 

73

%

 

78

%

 

71

%

 

75

%

Number of hospitals owned

 

19

   

19

   

19

   

19

   

19

   

19

   

19

   

19

 

2019

                               

Rehabilitation hospital

                               

Net operating revenues

 

$

50,615

   

$

48,080

   

$

55,863

   

$

51,991

   

$

56,019

   

$

52,364

   

$

160,374

   

$

314,932

 

Patient days

 

27,434

   

25,442

   

29,940

   

28,266

   

29,730

   

28,529

   

86,525

   

169,341

 

Occupancy rate

 

74

%

 

76

%

 

78

%

 

76

%

 

75

%

 

73

%

 

75

%

 

76

%

Number of hospitals owned

 

17

   

17

   

18

   

18

   

19

   

19

   

19

   

19

 

The following table summarizes the changes in net operating revenues and patient day volume for 2020, as compared to the same period in 2019, for each of the periods presented.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

Rehabilitation hospital

                               

Net operating revenues

 

21.8

%

 

26.2

%

 

6.8

%

 

(11.8)

%

 

3.2

%

 

24.1

%

 

5.2

%

 

11.4

%

Patient days

 

17.0

%

 

25.0

%

 

2.4

%

 

(16.7)

%

 

0.2

%

 

7.8

%

 

(2.8)

%

 

5.5

%

Outpatient Rehabilitation Segment.  Beginning in mid-March, hospitals and other facilities began to suspend elective surgeries. Additionally, state governments in the areas experiencing the most significant growth of COVID-19 infections began implementing mandatory closures of non-essential or non-life sustaining businesses, restrictions on individual activities outside of the home, restrictions on travel, and closures of schools. By the end of March, most states had implemented significant restrictions on businesses and individuals. The suspension of elective surgeries at hospitals and other facilities and the reduction of physician office visits, combined with recommendations of social distancing and the other items noted above, have had significant effects on patient visit volumes. Beginning in May, state governors and health departments began to ease the restrictions imposed at the beginning of the pandemic and hospitals began to perform elective surgeries again, which has increased the need for the services provided by Select Medical's outpatient rehabilitation clinics. Additionally, most physician offices have reopened for routine office visits. While some volume has recovered, Select Medical's outpatient rehabilitation segment continues to experience reduced volume of patients seeking rehabilitation services for employment injuries and sports activities.

The following table shows the trend in net operating revenues and patient visit volume for each of the periods presented, as well as the number of working days for each period.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months

Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

2020

                               

Outpatient Rehabilitation

                               

Net operating revenues

 

$

90,924

   

$

88,239

   

$

76,086

   

$

49,084

   

$

51,186

   

$

66,868

   

$

167,138

   

$

422,387

 

Visits

 

757,171

   

739,061

   

626,433

   

386,108

   

409,703

   

546,456

   

1,342,267

   

3,464,932

 

Working days(1)

 

22

   

20

   

22

   

22

   

20

   

22

     

64

     

128

 

2019

                               

Outpatient Rehabilitation

                               

Net operating revenues

 

$

83,185

   

$

78,573

   

$

85,147

   

$

90,230

   

$

90,272

   

$

81,389

   

$

261,891

   

$

508,796

 

Visits

 

687,007

   

658,610

   

708,866

   

762,914

   

759,829

   

680,762

   

2,203,505

   

4,257,988

 

Working days(1)

 

22

   

20

   

21

   

22

   

22

   

20

     

64

     

127

 
   

(1)

Represents the number of days in which normal business operations were conducted during the periods presented. 

The following table summarizes the changes in net operating revenues and patient visit volume for 2020, as compared to the same period in 2019, for each of the periods presented below.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

Outpatient Rehabilitation

                               

Net operating revenues

 

9.3

%

 

12.3

%

 

(10.6)

%

 

(45.6)

%

 

(43.3)

%

 

(17.8)

%

 

(36.2)

%

 

(17.0)

%

Visits

 

10.2

%

 

12.2

%

 

(11.6)

%

 

(49.4)

%

 

(46.1)

%

 

(19.7)

%

 

(39.1)

%

 

(18.6)

%

Concentra Segment.  Beginning in mid-March, state governments in the areas experiencing the most significant growth of COVID-19 infections began implementing mandatory closures of non-essential or non-life sustaining businesses. By the end of March, most states implemented significant restrictions on businesses, causing many employers to furlough their workforce and temporarily cease or significantly reduce their operations. These actions have had significant effects on patient visit volumes. Beginning in May, state governors and health departments began to ease the restrictions imposed at the beginning of the pandemic and employers began to increase their workforce, which has resulted in an increased need for occupational health services.

The following table shows the trend in net operating revenues and patient visit volume for each of the periods presented, as well as the number of working days for each period.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

2020

                               

Concentra

                               

Net operating revenues

 

$

141,236

   

$

133,690

   

$

123,609

   

$

91,178

   

$

99,228

   

$

121,932

   

$

312,338

   

$

710,873

 

Visits

 

1,032,069

   

965,741

   

879,585

   

610,555

   

674,629

   

865,896

   

2,151,080

   

5,028,475

 

Working days(1)

 

22

   

20

   

22

   

22

   

20

   

22

     

64

     

128

 

2019

                               

Concentra

                               

Net operating revenues

 

$

133,507

   

$

126,309

   

$

136,505

   

$

140,050

   

$

143,183

   

$

130,218

   

$

413,451

   

$

809,772

 

Visits

 

985,598

   

919,065

   

1,006,944

   

1,040,543

   

1,073,763

   

988,783

   

3,103,089

   

6,014,696

 

Working days(1)

 

22

   

20

   

21

   

22

   

22

   

20

     

64

     

127

 
   

(1)

Represents the number of days in which normal business operations were conducted during the periods presented. 

The following table summarizes the changes in net operating revenues and patient visit volume for 2020, as compared to the same period in 2019, for each of the periods presented below.

   

One Month Ended

 

Three Months
Ended June 30

 

Six Months
Ended June 30

   

January 31

 

February 28

 

March 31

 

April 30

 

May 31

 

June 30

   

Concentra

                               

Net operating revenues

 

5.8

%

 

5.8

%

 

(9.4)

%

 

(34.9)

%

 

(30.7)

%

 

(6.4)

%

 

(24.5)

%

 

(12.2)

%

Visits

 

4.7

%

 

5.1

%

 

(12.6)

%

 

(41.3)

%

 

(37.2)

%

 

(12.4)

%

 

(30.7)

%

 

(16.4)

%

Stock Repurchase Program

The board of directors of Select Medical has authorized a common stock repurchase program to repurchase up to $500.0 million worth of shares of its common stock. The program has been extended until December 31, 2020, and will remain in effect until then, unless further extended or earlier terminated by the board of directors. Stock repurchases under this program may be made in the open market or through privately negotiated transactions, and at times and in such amounts as Select Medical deems appropriate. Select Medical funds this program with cash on hand and borrowings under its revolving credit facility.

Select Medical did not repurchase shares during the quarter ended June 30, 2020. Since the inception of the program through June 30, 2020, Select Medical has repurchased 38,580,908 shares at a cost of approximately $356.6 million, or $9.24 per share, which includes transaction costs.

Conference Call

Select Medical will host a conference call regarding its second quarter results, as well as its business outlook and the impact of the COVID-19 pandemic on each of its reportable segments, on Friday, July 31, 2020, at 9:00am ET. The domestic dial in number for the call is 1-866-440-2669. The international dial in number is 1-409-220-9844. The conference ID for the call is 8496384. The conference call will be webcast simultaneously and can be accessed at Select Medical Holdings Corporation's website www.selectmedicalholdings.com.

For those unable to participate in the conference call, a replay will be available until 12:00pm ET, August 7, 2020. The replay number is 1-855-859-2056 (domestic) or 1-404-537-3406 (international). The conference ID for the replay will be 8496384. The replay can also be accessed at Select Medical Holdings Corporation's website, www.selectmedicalholdings.com.

Certain statements contained herein that are not descriptions of historical facts are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995).  Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

  • developments related to the COVID-19 pandemic including, but not limited to, the duration and severity of the pandemic, additional measures taken by government authorities and the private sector to limit the spread of COVID-19, and further legislative and regulatory actions which impact healthcare providers, including actions that may impact the Medicare program;
  • changes in government reimbursement for our services and/or new payment policies may result in a reduction in net operating revenues, an increase in costs, and a reduction in profitability;
  • the failure of our Medicare-certified long term care hospitals or inpatient rehabilitation facilities to maintain their Medicare certifications may cause our net operating revenues and profitability to decline;
  • the failure of our Medicare-certified long term care hospitals and inpatient rehabilitation facilities operated as "hospitals within hospitals" to qualify as hospitals separate from their host hospitals may cause our net operating revenues and profitability to decline;
  • a government investigation or assertion that we have violated applicable regulations may result in sanctions or reputational harm and increased costs;
  • acquisitions or joint ventures may prove difficult or unsuccessful, use significant resources or expose us to unforeseen liabilities;
  • our plans and expectations related to our acquisitions and our ability to realize anticipated synergies;
  • private third-party payors for our services may adopt payment policies that could limit our future net operating revenues and profitability;
  • the failure to maintain established relationships with the physicians in the areas we serve could reduce our net operating revenues and profitability;
  • shortages in qualified nurses, therapists, physicians, or other licensed providers, or the inability to attract or retain healthcare professionals due to the heightened risk of infection related to the COVID-19 pandemic, could increase our operating costs significantly or limit our ability to staff our facilities;
  • competition may limit our ability to grow and result in a decrease in our net operating revenues and profitability;
  • the loss of key members of our management team could significantly disrupt our operations;
  • the effect of claims asserted against us could subject us to substantial uninsured liabilities;
  • a security breach of our or our third-party vendors' information technology systems may subject us to potential legal and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 or the Health Information Technology for Economic and Clinical Health Act; and
  • other factors discussed from time to time in our filings with the Securities and Exchange Commission (the "SEC"), including factors discussed under the heading "Risk Factors" of the quarterly reports on Form 10-Q and of the annual report on Form 10-K for the year ended December 31, 2019.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:

Joel T. Veit
Senior Vice President and Treasurer
717-972-1100
ir@selectmedical.com

 

I. Condensed Consolidated Statements of Operations
For the Three Months Ended June 30, 2019 and 2020
(In thousands, except per share amounts, unaudited)

 
 

2019

 

2020

 

% Change

Net operating revenues

$

1,361,364

   

$

1,232,718

   

(9.4)

%

Costs and expenses:

         

Cost of services, exclusive of depreciation and amortization

1,150,150

   

1,082,456

   

(5.9)

 

General and administrative

31,339

   

33,461

   

6.8

 

Depreciation and amortization

54,993

   

52,271

   

(4.9)

 

Total costs and expenses

1,236,482

   

1,168,188

   

(5.5)

 

Other operating income

   

54,988

   

N/M

Income from operations

124,882

   

119,518

   

(4.3)

 

Other income and expense:

         

Equity in earnings of unconsolidated subsidiaries

7,394

   

8,324

   

12.6

 

Gain on sale of businesses

   

346

   

N/M

Interest expense

(51,464)

   

(37,366)

   

(27.4)

 

Income before income taxes

80,812

   

90,822

   

12.4

 

Income tax expense

20,826

   

23,336

   

12.1

 

Net income

59,986

   

67,486

   

12.5

 

Less: Net income attributable to non-controlling interests

15,170

   

15,836

   

4.4

 

Net income attributable to Select Medical

$

44,816

   

$

51,650

   

15.2

%

Diluted earnings per common share:(1)

$

0.33

   

$

0.39

     
   

(1)

Refer to table III for calculation of earnings per common share.

   

N/M

Not Meaningful

 

II. Condensed Consolidated Statements of Operations
For the Six Months Ended June 30, 2019 and 2020
(In thousands, except per share amounts, unaudited)

 
 

2019

 

2020

 

% Change

Net operating revenues

$

2,685,995

   

$

2,647,350

   

(1.4)

%

Costs and expenses:

         

Cost of services, exclusive of depreciation and amortization

2,282,242

   

2,282,827

   

0.0

 

General and administrative

60,016

   

67,292

   

12.1

 

Depreciation and amortization

107,131

   

104,023

   

(2.9)

 

Total costs and expenses

2,449,389

   

2,454,142

   

0.2

 

Other operating income

   

54,988

   

N/M

Income from operations

236,606

   

248,196

   

4.9

 

Other income and expense:

         

Equity in earnings of unconsolidated subsidiaries

11,760

   

10,912

   

(7.2)

 

Gain on sale of businesses

6,532

   

7,547

   

N/M

Interest expense

(102,275)

   

(83,473)

   

(18.4)

 

Income before income taxes

152,623

   

183,182

   

20.0

 

Income tax expense

39,293

   

45,248

   

15.2

 

Net income

113,330

   

137,934

   

21.7

 

Less: Net income attributable to non-controlling interests

27,680

   

33,159

   

19.8

 

Net income attributable to Select Medical

$

85,650

   

$

104,775

   

22.3

%

Diluted earnings per common share:(1)

$

0.63

   

$

0.78

     
   

(1)

Refer to table III for calculation of earnings per common share.

   

N/M

Not meaningful

 

III.  Earnings per Share
For the Three and Six Months Ended June 30, 2019 and 2020
(In thousands, except per share amounts, unaudited)

Select Medical's capital structure includes common stock and unvested restricted stock awards. To compute earnings per share ("EPS"), Select Medical applies the two-class method because its unvested restricted stock awards are participating securities which are entitled to participate equally with its common stock in undistributed earnings.

The following table sets forth the net income attributable to Select Medical, its common shares outstanding, and its participating securities outstanding for the three and six months ended June 30, 2019 and 2020:

   

Diluted EPS

   

Three Months Ended
June 30,

 

Six Months Ended
June 30,

   

2019

 

2020

 

2019

 

2020

Net income

 

$

59,986

   

$

67,486

   

$

113,330

   

$

137,934

 

Less: net income attributable to non-controlling interests

 

15,170

   

15,836

   

27,680

   

33,159

 

Net income attributable to Select Medical

 

44,816

   

51,650

   

85,650

   

104,775

 

Less: net income attributable to participating securities

 

1,484

   

1,778

   

2,826

   

3,596

 

Net income attributable to common shares

 

$

43,332

   

$

49,872

   

$

82,824

   

$

101,179

 

The following tables set forth the computation of EPS under the two-class method for the three and six months ended June 30, 2019 and 2020:

   

Three Months Ended June 30,

   

2019

   

2020

   

Net Income Allocation

 

Shares(1)

 

Diluted EPS

   

Net Income Allocation

 

Shares(1)

 

Diluted EPS

Common shares

 

$

43,332

   

130,562

   

$

0.33

     

$

49,872

   

129,319

   

$

0.39

 

Participating securities

 

1,484

   

4,471

   

$

0.33

     

1,778

   

4,610

   

$

0.39

 

Total

 

$

44,816

             

$

51,650

         
                                   
   

Six Months Ended June 30,

   

2019

   

2020

   

Net Income Allocation

 

Shares(1)

 

Diluted EPS

   

Net Income Allocation

 

Shares(1)

 

Diluted EPS

Common shares

 

$

82,824

   

130,711

   

$

0.63

     

$

101,179

   

129,479

   

$

0.78

 

Participating securities

 

2,826

   

4,460

   

$

0.63

     

3,596

   

4,602

   

$

0.78

 

Total

 

$

85,650

             

$

104,775

         
   

(1)

Represents the weighted average share count outstanding during the period.

 

IV.  Condensed Consolidated Balance Sheets
(In thousands, unaudited)

   

December 31, 2019

 

June 30, 2020

Assets

       

Current Assets:

       

Cash and cash equivalents

 

$

335,882

   

$

509,737

 

Accounts receivable

 

762,677

   

749,245

 

Other current assets

 

114,433

   

104,347

 

Total Current Assets

 

1,212,992

   

1,363,329

 

Operating lease right-of-use assets

 

1,003,986

   

1,022,721

 

Property and equipment, net

 

998,406

   

959,086

 

Goodwill

 

3,391,955

   

3,391,196

 

Identifiable intangible assets, net

 

409,068

   

398,266

 

Other assets

 

323,881

   

333,860

 

Total Assets

 

$

7,340,288

   

$

7,468,458

 

Liabilities and Equity

       

Current Liabilities:

       

Payables and accruals

 

$

681,163

   

$

663,348

 

Government advances

 

   

316,992

 

Unearned government assistance

 

   

45,505

 

Current operating lease liabilities

 

207,950

   

216,689

 

Current portion of long-term debt and notes payable

 

25,167

   

13,435

 

Total Current Liabilities

 

914,280

   

1,255,969

 

Non-current operating lease liabilities

 

852,897

   

866,097

 

Long-term debt, net of current portion

 

3,419,943

   

3,390,417

 

Non-current deferred tax liability

 

148,258

   

144,697

 

Other non-current liabilities

 

101,334

   

142,861

 

Total Liabilities

 

5,436,712

   

5,800,041

 

Redeemable non-controlling interests

 

974,541

   

495,987

 

Total equity

 

929,035

   

1,172,430

 

Total Liabilities and Equity

 

$

7,340,288

   

$

7,468,458

 

 

V.  Condensed Consolidated Statements of Cash Flows
For the Three Months Ended June 30, 2019 and 2020
(In thousands, unaudited)

   

2019

 

2020

Operating activities

       

Net income

 

$

59,986

   

$

67,486

 

Adjustments to reconcile net income to net cash provided by operating activities:

       

Distributions from unconsolidated subsidiaries

 

3,276

   

2,744

 

Depreciation and amortization

 

54,993

   

52,271

 

Provision for expected credit losses

 

391

   

54

 

Equity in earnings of unconsolidated subsidiaries

 

(7,394)

   

(8,324)

 

Gain on sale of assets and businesses

 

(121)

   

(542)

 

Stock compensation expense

 

6,358

   

6,963

 

Amortization of debt discount, premium and issuance costs

 

3,095

   

540

 

Deferred income taxes

 

(6,209)

   

(12,780)

 

Changes in operating assets and liabilities, net of effects of business combinations:

       

Accounts receivable

 

(11,121)

   

67,107

 

Other current assets

 

(1,713)

   

686

 

Other assets

 

(756)

   

9,256

 

Accounts payable and accrued expenses

 

(8,149)

   

61,726

 

Government advances

 

   

316,992

 

Unearned government assistance

 

   

45,505

 

Income taxes

 

(1,484)

   

32,330

 

Net cash provided by operating activities

 

91,152

   

642,014

 

Investing activities

       

Business combinations, net of cash acquired

 

(79,942)

   

(128)

 

Purchases of property and equipment

 

(40,212)

   

(32,045)

 

Investment in businesses

 

(24,649)

   

(4,901)

 

Proceeds from sale of assets and businesses

 

123

   

1,171

 

Net cash used in investing activities

 

(144,680)

   

(35,903)

 

Financing activities

       

Borrowings on revolving facilities

 

275,000

   

10,000

 

Payments on revolving facilities

 

(240,000)

   

(175,000)

 

Borrowings of other debt

 

5,940

   

25,000

 

Principal payments on other debt

 

(6,525)

   

(27,634)

 

Repurchase of common stock

 

(13,620)

   

(724)

 

Proceeds from exercise of stock options

 

459

   

 

Decrease in overdrafts

 

(3,874)

   

 

Proceeds from issuance of non-controlling interests

 

14,863

   

7

 

Distributions to and purchases of non-controlling interests

 

(2,494)

   

(1,186)

 

Net cash provided by (used in) financing activities

 

29,749

   

(169,537)

 

Net increase (decrease) in cash and cash equivalents

 

(23,779)

   

436,574

 

Cash and cash equivalents at beginning of period

 

147,815

   

73,163

 

Cash and cash equivalents at end of period

 

$

124,036

   

$

509,737

 

Supplemental information

       

Cash paid for interest

 

$

60,710

   

$

18,239

 

Cash paid for taxes

 

28,523

   

3,785

 

 

VI.  Condensed Consolidated Statements of Cash Flows
For the Six Months Ended June 30, 2019 and 2020
(In thousands, unaudited)

   

2019

 

2020

Operating activities

       

Net income

 

$

113,330

   

$

137,934

 

Adjustments to reconcile net income to net cash provided by operating activities:

       

Distributions from unconsolidated subsidiaries

 

11,148

   

11,223

 

Depreciation and amortization

 

107,131

   

104,023

 

Provision for expected credit losses

 

1,958

   

253

 

Equity in earnings of unconsolidated subsidiaries

 

(11,760)

   

(10,912)

 

Gain on sale of assets and businesses

 

(6,354)

   

(7,881)

 

Stock compensation expense

 

12,613

   

13,866

 

Amortization of debt discount, premium and issuance costs

 

6,326

   

1,093

 

Deferred income taxes

 

(6,290)

   

(3,416)

 

Changes in operating assets and liabilities, net of effects of business combinations:

       

Accounts receivable

 

(85,873)

   

13,179

 

Other current assets

 

(9,236)

   

713

 

Other assets

 

(939)

   

11,504

 

Accounts payable and accrued expenses

 

(15,486)

   

8,279

 

Government advances

 

   

316,992

 

Unearned government assistance

 

   

45,505

 

Income taxes

 

16,346

   

43,743

 

Net cash provided by operating activities

 

132,914

   

686,098

 

Investing activities

       

Business combinations, net of cash acquired

 

(86,062)

   

(6,961)

 

Purchases of property and equipment

 

(89,285)

   

(71,253)

 

Investment in businesses

 

(52,257)

   

(14,749)

 

Proceeds from sale of assets and businesses

 

125

   

12,401

 

Net cash used in investing activities

 

(227,479)

   

(80,562)

 

Financing activities

       

Borrowings on revolving facilities

 

635,000

   

470,000

 

Payments on revolving facilities

 

(460,000)

   

(470,000)

 

Payments on term loans

 

(132,685)

   

(39,843)

 

Borrowings of other debt

 

14,230

   

31,487

 

Principal payments on other debt

 

(12,680)

   

(35,733)

 

Repurchase of common stock

 

(13,620)

   

(9,415)

 

Proceeds from exercise of stock options

 

459

   

 

Increase in overdrafts

 

2,176

   

 

Proceeds from issuance of non-controlling interests

 

18,288

   

1,686

 

Distributions to and purchases of non-controlling interests

 

(7,745)

   

(13,660)

 

Purchase of membership interests of Concentra Group Holdings Parent

 

   

(366,203)

 

Net cash provided by (used in) financing activities

 

43,423

   

(431,681)

 

Net increase (decrease) in cash and cash equivalents

 

(51,142)

   

173,855

 

Cash and cash equivalents at beginning of period

 

175,178

   

335,882

 

Cash and cash equivalents at end of period

 

$

124,036

   

$

509,737

 

Supplemental information

       

Cash paid for interest

 

$

97,909

   

$

86,124

 

Cash paid for taxes

 

29,241

   

4,920

 

 

VII.  Key Statistics
For the Three Months Ended June 30, 2019 and 2020
(unaudited)

   

2019

 

2020

 

% Change

Critical Illness Recovery Hospital

           

Number of hospitals – end of period(a)

 

100

   

101

     

Net operating revenues (,000)

 

$

461,143

   

$

519,626

   

12.7

%

Number of patient days(b)(c)

 

262,860

   

276,889

   

5.3

%

Number of admissions(b)(d)

 

9,172

   

9,167

   

(0.1)

%

Net revenue per patient day(b)(e)

 

$

1,739

   

$

1,867

   

7.4

%

Adjusted EBITDA (,000)

 

$

64,138

   

$

89,743

   

39.9

%

Adjusted EBITDA margin

 

13.9

%

 

17.3

%

   

Rehabilitation Hospital

           

Number of hospitals – end of period(a)

 

28

   

29

     

Net operating revenues (,000)

 

$

160,374

   

$

168,667

   

5.2

%

Number of patient days(b)(c)

 

86,525

   

84,081

   

(2.8)

%

Number of admissions(b)(d)

 

6,017

   

5,713

   

(5.1)

%

Net revenue per patient day(b)(e)

 

$

1,635

   

$

1,831

   

12.0

%

Adjusted EBITDA (,000)

 

$

29,968

   

$

27,605

   

(7.9)

%

Adjusted EBITDA margin

 

18.7

%

 

16.4

%

   

Outpatient Rehabilitation

           

Number of clinics – end of period(a)

 

1,695

   

1,757

     

Net operating revenues (,000)

 

$

261,891

   

$

167,138

   

(36.2)

%

Number of visits(b)

 

2,203,505

   

1,342,267

   

(39.1)

%

Revenue per visit(b)(f)

 

$

102

   

$

106

   

3.9

%

Adjusted EBITDA (,000)

 

$

42,584

   

$

(6,282)

   

(114.8)

%

Adjusted EBITDA margin

 

16.3

%

 

(3.8)

%

   

Concentra

           

Number of centers – end of period(b)

 

526

   

522

     

Net operating revenues (,000)

 

$

413,451

   

$

312,338

   

(24.5)

%

Number of visits(b)

 

3,103,089

   

2,151,080

   

(30.7)

%

Revenue per visit(b)(f)

 

$

121

   

$

124

   

2.5

%

Adjusted EBITDA (,000)

 

$

76,087

   

$

41,497

   

(45.5)

%

Adjusted EBITDA margin

 

18.4

%

 

13.3

%

   
   

(a)

Includes managed locations.

   

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

   

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

   

(d)

Represents the number of patients admitted to our hospitals during the periods presented.

   

(e)      

Represents the average amount of revenue recognized for each patient day. Net revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

   

(f)       

Represents the average amount of revenue recognized for each patient visit. Net revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits.

 

VIII.  Key Statistics
For the Six Months Ended June 30, 2019 and 2020
(unaudited)

   

2019

 

2020

 

% Change

Critical Illness Recovery Hospital

           

Number of hospitals – end of period(a)

 

100

   

101

     

Net operating revenues (,000)

 

$

918,677

   

$

1,020,147

   

11.0

%

Number of patient days(b)(c)

 

520,989

   

547,347

   

5.1

%

Number of admissions(b)(d)

 

18,628

   

18,700

   

0.4

%

Net revenue per patient day(b)(e)

 

$

1,749

   

$

1,853

   

5.9

%

Adjusted EBITDA (,000)

 

$

137,136

   

$

178,313

   

30.0

%

Adjusted EBITDA margin

 

14.9

%

 

17.5

%

   

Rehabilitation Hospital

           

Number of hospitals – end of period(a)

 

28

   

29

     

Net operating revenues (,000)

 

$

314,932

   

$

350,686

   

11.4

%

Number of patient days(b)(c)

 

169,341

   

178,649

   

5.5

%

Number of admissions(b)(d)

 

11,853

   

12,046

   

1.6

%

Net revenue per patient day(b)(e)

 

$

1,634

   

$

1,778

   

8.8

%

Adjusted EBITDA (,000)

 

$

55,765

   

$

66,174

   

18.7

%

Adjusted EBITDA margin

 

17.7

%

 

18.9

%

   

Outpatient Rehabilitation

           

Number of clinics – end of period(a)

 

1,695

   

1,757

     

Net operating revenues (,000)

 

$

508,796

   

$

422,387

   

(17.0)

%

Number of visits(b)

 

4,257,988

   

3,464,932

   

(18.6)

%

Revenue per visit(b)(f)

 

$

103

   

$

105

   

1.9

%

Adjusted EBITDA (,000)

 

$

71,575

   

$

20,840

   

(70.9)

%

Adjusted EBITDA margin

 

14.1

%

 

4.9

%

   

Concentra

           

Number of centers – end of period(b)

 

526

   

522

     

Net operating revenues (,000)

 

$

809,772

   

$

710,873

   

(12.2)

%

Number of visits(b)

 

6,014,696

   

5,028,475

   

(16.4)

%

Revenue per visit(b)(f)

 

$

122

   

$

124

   

1.6

%

Adjusted EBITDA (,000)

 

$

142,345

   

$

102,963

   

(27.7)

%

Adjusted EBITDA margin

 

17.6

%

 

14.5

%

   
 

(a)

Includes managed locations.

   

(b)

Excludes managed locations. For purposes of the Concentra segment, onsite clinics and community-based outpatient clinics are excluded.

   

(c)

Each patient day represents one patient occupying one bed for one day during the periods presented.

   

(d)

Represents the number of patients admitted to our hospitals during the periods presented.

   

(e)      

Represents the average amount of revenue recognized for each patient day. Net revenue per patient day is calculated by dividing patient service revenues, excluding revenues from certain other ancillary and outpatient services provided at our hospitals, by the total number of patient days.

   

(f)       

Represents the average amount of revenue recognized for each patient visit. Net revenue per visit is calculated by dividing patient service revenue, excluding revenues from certain other ancillary services, by the total number of visits.

 

IX. Net Income to Adjusted EBITDA Reconciliation
For the Three and Six Months Ended June 30, 2019 and 2020
(In thousands, unaudited)

The presentation of Adjusted EBITDA is important to investors because Adjusted EBITDA is commonly used as an analytical indicator of performance by investors within the healthcare industry. Adjusted EBITDA is used to evaluate financial performance and determine resource allocation for each of Select Medical's operating segments. Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles ("GAAP"). Items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to, or substitute for, net income, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying definitions, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies.

The following table reconciles net income to Adjusted EBITDA for Select Medical. Adjusted EBITDA is used by Select Medical to report its segment performance. Adjusted EBITDA is defined as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, gain (loss) on sale of businesses, and equity in earnings (losses) of unconsolidated subsidiaries.

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

2019

 

2020

 

2019

 

2020

Net income

$

59,986

   

$

67,486

   

$

113,330

   

$

137,934

 

Income tax expense

20,826

   

23,336

   

39,293

   

45,248

 

Interest expense

51,464

   

37,366

   

102,275

   

83,473

 

Gain on sale of businesses

   

(346)

   

(6,532)

   

(7,547)

 

Equity in earnings of unconsolidated subsidiaries

(7,394)

   

(8,324)

   

(11,760)

   

(10,912)

 

Income from operations

124,882

   

119,518

   

236,606

   

248,196

 

Stock compensation expense:

             

Included in general and administrative

4,796

   

5,451

   

9,544

   

10,888

 

Included in cost of services

1,562

   

1,512

   

3,069

   

2,978

 

Depreciation and amortization

54,993

   

52,271

   

107,131

   

104,023

 

Adjusted EBITDA

$

186,233

   

$

178,752

   

$

356,350

   

$

366,085

 
               

Critical illness recovery hospital

$

64,138

   

$

89,743

   

$

137,136

   

$

178,313

 

Rehabilitation hospital

29,968

   

27,605

   

55,765

   

66,174

 

Outpatient rehabilitation

42,584

   

(6,282)

   

71,575

   

20,840

 

Concentra(a)

76,087

   

41,497

   

142,345

   

102,963

 

Other(a)(b)

(26,544)

   

26,189

   

(50,471)

   

(2,205)

 

Adjusted EBITDA

$

186,233

   

$

178,752

   

$

356,350

   

$

366,085

 
   

(a)

For the three and six months ended June 30, 2020, Select Medical recognized approximately $55.0 million of other operating income related to payments received under the Provider Relief Fund for loss of revenue and health care related expenses attributable to COVID-19. $54.2 million of other operating income is included within the operating results of Select Medical's other activities; $0.8 million of other operating income is included in the operating results of Select Medical's Concentra segment.

   

(b)

Other primarily includes general and administrative costs.

 

X. Reconciliation of Earnings per Common Share to Adjusted Earnings per Common Share
For the Three and Six Months Ended June 30, 2019 and 2020
(
In thousands, except per share amounts, unaudited)

Adjusted net income attributable to common shares and adjusted earnings per common share are not measures of financial performance under GAAP.  Items excluded from adjusted net income attributable to common shares and adjusted earnings per common share are significant components in understanding and assessing financial performance. Select Medical believes that the presentation of adjusted net income attributable to common shares and adjusted earnings per common share are important to investors because they are reflective of the financial performance of Select Medical's ongoing operations and provide better comparability of its results of operations between periods. Adjusted net income attributable to common shares and adjusted earnings per common share should not be considered in isolation or as alternatives to, or substitutes for, net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted net income attributable to common shares and adjusted earnings per common share are not measurements determined in accordance with GAAP and are thus susceptible to varying calculations, adjusted net income attributable to common shares and adjusted earnings per common share as presented may not be comparable to other similarly titled measures of other companies.

The following tables reconcile net income attributable to common shares and earnings per common share on a fully diluted basis to adjusted net income attributable to common shares and adjusted earnings per common share on a fully diluted basis.

 

Three Months Ended June 30,

 

2019

 

Per Share(a)

 

2020

 

Per Share(a)

Net income attributable to common shares(a)

$

43,332

   

$

0.33

   

$

49,872

   

$

0.39

 

Adjustments:(b)

             

Gain on sale of businesses

   

   

(249)

   

(0.01)

 

Adjusted net income attributable to common shares

$

43,332

   

$

0.33

   

$

49,623

   

$

0.38

 
   
 

Six Months Ended June 30,

 

2019

 

Per Share(a)

 

2020

 

Per Share(a)

Net income attributable to common shares(a)

$

82,824

   

$

0.63

   

$

101,179

   

$

0.78

 

Adjustments:(b)

             

Gain on sale of businesses

(4,545)

   

(0.03)

   

(3,900)

   

(0.03)

 

Adjusted net income attributable to common shares

$

78,279

   

$

0.60

   

$

97,279

   

$

0.75

 
 

(a)

Net income attributable to common shares and earnings per common share are calculated based on the diluted weighted average common shares outstanding, as presented in table III.

   

(b)

Adjustments to net income attributable to common shares include estimated income tax and non-controlling interest impacts and are calculated based on the diluted weighted average common shares outstanding.

   
 

The estimated income tax impact, which is determined using tax rates based on the nature of the adjustment and the jurisdiction in which the adjustment occurred, includes both current and deferred income tax expense or benefit.

   
 

For the three months ended June 30, 2020, the adjustment to net income attributable to common shares includes estimated income tax expense of approximately $0.1 million.

   
 

For the six months ended June 30, 2019 and 2020, the adjustments to net income attributable to common shares include estimated income tax expense of approximately $1.8 million and $3.5 million, respectively.

 

Cision View original content:http://www.prnewswire.com/news-releases/select-medical-holdings-corporation-announces-results-for-its-second-quarter-ended-june-30-2020-301103479.html

SOURCE Select Medical Holdings Corporation

 
 
Company Codes: NYSE:SEM
 
MORE ON THIS TOPIC